SEC Form 4 · accession 0001615774-18-006006

Tonix Pharmaceuticals Holding Corp. · TNXP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Jun 28, 2018

Accepted (ET)

Jun 29, 2018 · 4:30 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001430306

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, $0.001 par value^F1	Jun 28, 2018	P	500	$4.58	A	17,166	D
Common Stock, $0.001 par value	holding	—	—		—	22,700	I	By 401(k) plan
Common Stock, $0.001 par value	holding	—	—		—	45,900	I	By IRA account
Common Stock, $0.001 par value	holding	—	—		—	3,100	I	By spouse
Common Stock, $0.001 par value^F2	holding	—	—		—	2,917	I	By Leder Laboratories, Inc.
Common Stock, $0.001 par value^F2	holding	—	—		—	2,917	I	By Starling Pharmaceuticals, Inc.
Common Stock, $0.001 par value^F2	holding	—	—		—	20,463	I	By Lederman & Co., LLC
Common Stock, $0.001 par value^F2	holding	—	—		—	3,246	I	By L&L Technologies, LLC
Common Stock, $0.001 par value^F2	holding	—	—		—	5,898	I	By Targent Pharmaceuticals, LLC

No Table II lines on this filing.

F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.57 to $4.59 per share, inclusive. The reporting person undertakes to provide to Tonix Pharmaceuticals Holding Corp. ("Tonix"), any security holder of Tonix, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
F2Reporting person may be deemed to be a control person of this entity.